U.S. markets closed

Immunic, Inc. (IMUX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
18.38+0.49 (+2.74%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close17.89
Open18.05
Bid18.00 x 1000
Ask18.61 x 1000
Day's Range17.66 - 18.50
52 Week Range4.19 - 23.39
Volume1,097,195
Avg. Volume643,950
Market Cap380.802M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.28
Earnings DateAug 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
    PR Newswire

    Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

    Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the full unblinded clinical data set from the company's phase 2 EMPhASIS trial of lead asset, IMU-838, a selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS) is now available and expands on and confirms the company's previously announced positive top-line results. A summary will be presented at the MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting, taking place September 11-13, 2020, online, by Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio.

  • Immunic, Inc. to Participate in Scientific and Investor Conferences in September
    PR Newswire

    Immunic, Inc. to Participate in Scientific and Investor Conferences in September

    Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in September:

  • Why Immunic Stock Is Soaring Today
    Motley Fool

    Why Immunic Stock Is Soaring Today

    Shares of Immunic (NASDAQ: IMUX) are up by 18% as of 1:30 p.m. EDT on Wednesday, despite the clinical-stage biopharmaceutical company not reporting any news. IMU-838 achieved all its primary and secondary endpoints in the study, and these positive results are one of the main reasons why Piper Sandler analyst Yasmeen Rahimi initiated coverage on the company's stock with an overweight (buy) rating. After all, the clinical trial process is rife with risk and uncertainty, and if one of the company's candidates fails to deliver positive results, its stock will plunge.